timothy sykes logo

Stock News

Pasithea Therapeutics Stock Surges with New Public Offering and Promising Trial Results

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 11/29/2025, 8:10 am ET | 5 min
Pasithea Therapeutics Stock Surges with New Public Offering and Promising Trial Results Thumbnail

In this article Last trade Nov, 28 4:59 PM

  • KTTA+18.87%
    KTTA - NASDAQPasithea Therapeutics Corp.
    $1.26+0.20 (+18.87%)
    Volume:  166.50M
    Float:  7.24M
    $0.88Day Low/High$2.06

Pasithea Therapeutics Corp.’s stocks have been trading up by 18.87 percent, boosted by promising results and FDA designations.

Healthcare industry expert:

Analyst sentiment – neutral

Pasithea Therapeutics (KTTA) holds a challenging market position with negative profitability margins and deteriorating income statements. The company’s enterprise value stands at $117 million with a price-to-book value of 0.65, indicating some market skepticism. Despite the 100% three-year revenue decline, the company shows a strong balance sheet with a perfect debt-to-equity ratio of zero and a robust current ratio of 4. This sound financial standing, however, does not obscure concerning efficiency metrics like a return on equity of -89.9% and return on assets of -83.64%, highlighting severe operational inefficiencies.

In examining the stock’s technical performance, recent weekly price movements suggest volatility with significant surges seen mid-week. From a trading perspective, the dominant trend is bullish particularly evidenced by a sharp rise on November 28, 2025, where price opened higher at $1.27 with a high of $1.3, closing just below this at $1.26. The price surge aligned with heightened trading volumes post-public offering announcement, supporting a momentum-driven strategy. Traders should consider key resistance close to $1.50 and support around $0.75, leveraging breakout strategies for potential gains.

The recent strategic maneuvers, particularly positive trial data for PAS-004 and a $60 million capital influx via a public offering, significantly impact Pasithea’s outlook. The stock’s positive price response, with a rise of up to 54%, suggests investor resilience and potential for long-term growth. Phase 1 and 1b trials showing promising results provide a solid foundation in its core Biotech endeavors. However, comparative analysis to sector benchmarks reveals a higher speculation risk. Investors should cautiously watch for any developments at the $0.75 support level, which aligns with the public offering price, signifying a key psychological and technical threshold.

Candlestick Chart

Weekly Update Nov 24 – Nov 28, 2025: On Saturday, November 29, 2025 Pasithea Therapeutics Corp. stock [NASDAQ: KTTA] is trending up by 18.87%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

During recent trading sessions, Pasithea’s stock fluctuation mirrored the broader market reaction to their strategic financial maneuvers. Initially priced at $0.75 per share, the market responded positively, propelling the stock by 54% at its peak. With an open price at $1.27 on November 28, KTTA showed resilience by closing at $1.26, signaling strong investor trust. This upswing in share value is corroborated by the announcement of promising trial results and a substantial public offering aimed at raising $60 million for strategic enhancements in clinical trials and acquisitions.

More Breaking News

The offering has significantly improved the balance sheet outlook, aiming for a financially strategic leverage through investor confidence and enhanced liquidity. Key ratios displayed favorable management effectiveness amidst challenges, with total assets recorded at $13.63M and equity standing firm, which indicates a grounded financial structure. With zero debt-to-equity indicative of prudent fiscal management, KTTA’s current ratio at 4 underscores its healthy liquidity position, enhancing its operational viability until at least mid-2028.

Conclusion

Pasithea Therapeutics is clearly navigating a promising path, underscored by strategic capital-raising schemes and successful clinical data outcomes. The steady rise in KTTA’s stock price mirrors trader trust and optimism in its product pipeline and financial health. As it continues to harness substantial market interest and bolstered by pivotal interim trial results, the firm’s future looks promising, driving expectations of continued positive performances. As millionaire penny stock trader and teacher Tim Sykes says, “It’s better to go home at zero than to go home in the red,” which reflects the importance of Pasithea’s cautious yet strategic trading approach. The systematic financial approach, combined with innovative therapeutic advancements, marks potential sustainable growth and competitive advantage moving forward.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”